0001214659-23-014606.txt : 20231106 0001214659-23-014606.hdr.sgml : 20231106 20231106161437 ACCESSION NUMBER: 0001214659-23-014606 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231102 FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leproust Emily M. CENTRAL INDEX KEY: 0001753655 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38720 FILM NUMBER: 231380121 MAIL ADDRESS: STREET 1: C/O TWIST BIOSCIENCE CORPORATION STREET 2: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Twist Bioscience Corp CENTRAL INDEX KEY: 0001581280 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462058888 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 800-719-0671 MAIL ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 marketforms-63445.xml PRIMARY DOCUMENT X0508 4 2023-11-02 0001581280 Twist Bioscience Corp TWST 0001753655 Leproust Emily M. C/O TWIST BIOSCIENCE CORPORATION 681 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 true true false false Chief Executive Officer 0 Common Stock 2023-11-02 4 A false 44611 0 A 368468 D Common Stock 2023-11-02 4 F false 8223 17.31 D 360245 D Common Stock 2023-11-02 4 A false 168976 0 A 529221 D Employee Stock Option (right to buy) 5.95 2025-09-28 Common Stock 0 24360 D Employee Stock Option (right to buy) 8.82 2027-09-28 Common Stock 0 150879 D Employee Stock Option (right to buy) 26.66 2028-11-18 Common Stock 0 266539 D Employee Stock Option (right to buy) 23.33 2029-10-23 Common Stock 0 131290 D Employee Stock Option (right to buy) 67.85 2022-12-19 2030-08-31 Common Stock 64950 64950 D Represents performance stock units for which target criteria was determined to have been met on November 2, 2023. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2024, subject to continued service or acceleration of vesting as provided in the award agreement. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 2, 2023 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. /s/ Alyssa Zhang, as Attorney-in-Fact for Emily M. Leproust 2023-11-06